Michinari Hirata
Overview
Explore the profile of Michinari Hirata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi Y, Ueyama A, Funaki S, Jinushi K, Higuchi N, Morihara H, et al.
BMC Cancer
. 2024 May;
24(1):627.
PMID: 38783281
Background: CCR8-expressing regulatory T cells (Tregs) are selectively localized within tumors and have gained attention as potent suppressors of anti-tumor immunity. This study focused on CCR8 Tregs and their interaction...
2.
Tone M, Iwahori K, Hirata M, Ueyama A, Tani A, Haruta J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38621815
Background: Cancer immunotherapy including immune checkpoint inhibitors is only effective for a limited population of patients with cancer. Therefore, the development of novel cancer immunotherapy is anticipated. In preliminary studies,...
3.
Nagira Y, Nagira M, Nagai R, Nogami W, Hirata M, Ueyama A, et al.
Mol Cancer Ther
. 2023 Jul;
22(9):1063-1072.
PMID: 37420296
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction...
4.
Isono T, Iwahori K, Yanagawa M, Yamamoto Y, Tone M, Haruna M, et al.
Lung Cancer
. 2023 Jun;
182:107278.
PMID: 37321075
Objectives: Limited treatment options are available for non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD). The rationale for immunotherapy and its adverse events for NSCLC with ILD...
5.
Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, et al.
Cancer Immunol Immunother
. 2022 Jul;
72(1):169-181.
PMID: 35776160
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy...
6.
Kajikawa H, Hirata M, Haruna M, Ueyama A, Hirose K, Kawashima A, et al.
Anticancer Res
. 2022 Apr;
42(5):2383-2393.
PMID: 35489733
Background: Tumor immunity in the tumor microenvironment is activated in patients with feasible clinical responses to immune checkpoint inhibitors. The immunological profile of tumor-infiltrating lymphocytes (TILs) obtained from patients with...
7.
Noguchi Y, Yamamoto Y, Iwahori K, Matsumoto M, Hirata M, Okuyama H, et al.
Biol Pharm Bull
. 2022 Apr;
45(4):429-437.
PMID: 35370267
Cancer immunotherapies are powerful therapeutic options for cancer patients. To enhance the therapeutic effects of cancer immunotherapies, we plan to develop novel immunostimulatory drugs for use in combination with cancer...
8.
Haruna M, Ueyama A, Yamamoto Y, Hirata M, Goto K, Yoshida H, et al.
Sci Rep
. 2022 Mar;
12(1):5377.
PMID: 35354899
Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments. Recent studies...
9.
Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, et al.
Proc Natl Acad Sci U S A
. 2022 Feb;
119(7).
PMID: 35140181
Foxp3-expressing CD25CD4 regulatory T cells (Tregs) are abundant in tumor tissues. Here, hypothesizing that tumor Tregs would clonally expand after they are activated by tumor-associated antigens to suppress antitumor immune...
10.
Urakawa S, Yamasaki M, Makino T, Kurokawa Y, Yamamoto K, Goto K, et al.
Cancer Immunol Immunother
. 2020 Aug;
70(2):443-452.
PMID: 32803278
It remains unclear whether Helicobacter pylori (H. pylori), a major cause of gastric cancer (GC), is involved in other intestinal cancers. In our previous study, ICOS Foxp3 CD4 T cells...